Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) had its target price dropped by stock analysts at Citizens Jmp from $62.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price suggests a potential upside of 210.03% from the company’s previous close.
A number of other research analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday. Mizuho raised their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday. Wedbush lowered their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.13.
Check Out Our Latest Research Report on AVTX
Avalo Therapeutics Stock Down 6.7%
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, research analysts predict that Avalo Therapeutics will post -3.03 earnings per share for the current fiscal year.
Insider Transactions at Avalo Therapeutics
In related news, CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares of the company’s stock, valued at $116,239.20. This trade represents a 48.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. This represents a 95.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 138,078 shares of company stock valued at $2,501,346. Company insiders own 4.46% of the company’s stock.
Hedge Funds Weigh In On Avalo Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC lifted its holdings in Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock valued at $20,019,000 after purchasing an additional 289,786 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Avalo Therapeutics by 556.4% during the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock valued at $1,793,000 after purchasing an additional 101,814 shares during the last quarter. Sei Investments Co. bought a new position in Avalo Therapeutics during the 1st quarter valued at about $849,000. Dimensional Fund Advisors LP bought a new position in Avalo Therapeutics during the 1st quarter valued at about $607,000. Finally, AlphaCentric Advisors LLC bought a new position in Avalo Therapeutics during the 1st quarter valued at about $174,000. 87.06% of the stock is owned by institutional investors.
Trending Headlines about Avalo Therapeutics
Here are the key news stories impacting Avalo Therapeutics this week:
- Positive Sentiment: Mizuho raised its price target on Avalo Therapeutics to $45 from $39 and maintained an outperform rating, signaling continued optimism about the company’s longer-term potential. Avalo Therapeutics (NASDAQ:AVTX) Given New $45.00 Price Target at Mizuho
- Positive Sentiment: HC Wainwright reiterated a buy rating and set a $35 target, while Citizens JMP kept a market outperform stance with a $55 target, suggesting analysts still see substantial upside despite trimming estimates. Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens Jmp Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $35.00 at HC Wainwright
- Neutral Sentiment: Several firms adjusted their valuation targets in both directions, including Wedbush cutting its target to $34 and Citizens JMP lowering its target to $55, which may be contributing to volatility but does not signal a bearish consensus. Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at Wedbush
- Negative Sentiment: The company also urged investors to review Form 10-Q risk factors amid ongoing uncertainty, which is likely pressuring shares by reminding the market of regulatory and execution risks. Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
